7 results about "Methylprednisolone" patented technology

The invention discloses application of quercidic acid in preparation of a medicine or a medicine composition for preventing or treating diseases or symptoms related to excessive glucocorticoid. According to the application disclosed by the invention, the protective effect of the quercidic acid on the GIONFH is verified through a preclinical model, and evidence that the quercidic acid can be applied to prevention or treatment of the GIONFH is provided. Animal experiments prove that the quercidic acid can inhibit methylprednisolone-induced rat GIONFH, and the action mechanism is related to inhibition of osteoclasts. The medicine or the medicine composition described by the invention can obviously improve the formation of necrotic fossa in femoral head of GIONFH, bone loss of bone trabecula, CTSK positive cell expression, osteoclast formation, bone resorption protein expression and osteoclast overactivity at a lower dosage, and provides a potential prevention and treatment scheme for treatment of GIONFH.

The invention relates to the technical field of pharmaceutical preparations, in particular to a methylprednisolone pulse micro-tablet and a preparation method thereof. The methylprednisolone pulse microtablet comprises a quick release tablet core and a coating layer, the quick-release tablet core comprises methylprednisolone, a filler, an antistatic agent A, an antistatic agent B, an adhesive and a lubricant; the coating layer comprises a coating material and a plasticizer; wherein the antistatic agent A is selected from at least one of a combination of organic acid and bicarbonate or ammonium carbonate; the antistatic agent B is selected from at least one of polyoxyethylene, carbomer, high-expansion type pregelatinized starch, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, croscarmellose sodium and crospovidone. The antistatic agent A and the antistatic agent B have a synergistic effect, so that the electrostatic phenomenon can be effectively reduced, and particle adhesion and microchip agglomeration are avoided.

The invention belongs to the technical field of chemical synthesis, and particularly relates to a preparation method of methylprednisolone and an intermediate compound thereof. The preparation method comprises the following steps: by taking cortisone as a raw material, carrying out 17 and 21 site upper protecting groups and 3 site upper protecting groups, and carrying out reduction, so as to obtain a methylprednisolone intermediate compound shown as a formula V; and carrying out 5 and 6-site epoxidation, Grignard reaction, 3-site protecting group removal, 4 and 5-site dehydration elimination, 1 and 2-site dehydrogenation and 17 and 21-site protecting group removal on the compound in the formula V to obtain methylprednisolone. The structural formula of the compound of formula V is shown in the specification. The preparation process has the advantages of high yield, high purity, low cost, simplicity in operation and suitability for industrial production.

The invention provides an application of metformin in preparation of a medicine for preventing or treating immune checkpoint inhibitor related colitis. It is found through experiments that when the immune checkpoint inhibitor causes colitis, change of metabolic level represented by glycolysis caused by change of a PI3K / AKT / mTOR pathway in the colon is obviously accompanied, then Treg / Th17 steady state in the colon is affected, and a high inflammatory state is shown in the colon. According to the present invention, the influence on glycolysis and other metabolic pathways is achieved through the targeted interference of the metformin on the PI3K / AKT / mTOR pathway, the colitis caused by the immune checkpoint inhibitor can be significantly improved, the anti-tumor drug effect of the immune checkpoint inhibitor is not affected, and the method is generally superior to the original clinical methylprednisolone intervention scheme.

This invention relates to a lipid nanoparticle delivery system, its preparation method, and its applications, belonging to the fields of biomedicine and vaccine technology. The lipid nanoparticles include immunomodulatory components, cationic lipids, helper phospholipids, sterol lipids, and polyethylene glycol-modified lipids, wherein the immunomodulatory component is methylprednisolone or squalene. When the immunomodulatory component is methylprednisolone, LNPs exhibit higher levels of cytokines related to the activation of innate immunity, suggesting enhanced humoral immune responses. When the immunomodulatory component is squalene, LNPs exhibit higher muscle retention, suggesting potentially higher biocompatibility, better immunogenicity, and enhanced T-cell responses.

The invention discloses a preparation method of a composite scaffold for multi-period controlled release of methylprednisolone. The composite scaffold is composed of chitosan hydrogel loaded with methylprednisolone and a polycaprolactone fiber membrane loaded with methylprednisolone. The preparation method of the methylprednisolone-loaded polycaprolactone fiber membrane comprises the following steps: mixing polycaprolactone particles with methylprednisolone, dissolving by using a mixed solution of trichloromethane and methanol, and preparing the solution into the fiber membrane by using an electrostatic spinning technology. And mixing the chitosan hydrogel loaded with the methylprednisolone with a polycaprolactone fiber membrane to prepare the composite scaffold. The preparation method is simple in process and low in cost, in-vitro drug release experiment research shows that the controlled release effect of methylprednisolone can be used for marking a clinical treatment scheme, and cell experiments and animal experiments prove that the composite scaffold has the advantages of biocompatibility, inhibition of inflammatory factor release, inhibition of M1 type polarization of immune cells and the like.